Break the cycle of severe chronic pain

Palexia® PR Prolonged Release (PR) is indicated for the management of severe chronic pain in adults, which can be adequately managed only with opioid analgesics1

Pain relief is important in helping patients reduce other symptoms and achieve other gains such as improving sleep quality, but patients with chronic (low back) pain also tend to value other domains, beyond pain, as important outcomes of treatment.2-4

Other treatment outcomes, including physical functioning, social functioning and emotional well-being, play a significant role in patient’s perception of improvement.2-4

About Palexia® PR

Explore Palexia® PR for Efficacy, Mechanism of Action and Safety & Tolerability profile


Learn how Palexia® PR improves quality of life and functional outcomes8* and provides effective pain control to help your patients navigate the physical and social aspects of daily living8,9*
... Know more

Why Palexia® PR

How can Palexia® PR support improvements in functional outcomes in severe chronic low back pain patients?

Palexia® PR contains the atypical opioid tapentadol.1,5 It has a synergistic, dual mechanism of action6,7 and is specifically designed to treat severe chronic (low back) pain1, providing:

*In severe chronic low back pain with a neuropathic component.

Tools and Resources


Lien externe:

Vous êtes sur le point de quitter le site Grü et allez être redirigé vers un ou plusieurs autres sites y compris les sites du Groupe Grünenthal. Pour plus d'informations au sujet des liens hypertextes proposés, veuillez consulter les conditions d'utilisation. Cliquer sur Continuer ou sur Retour pour revenir à la page précédente.

... Retour ... Continuer